Literature DB >> 8981571

Pharmacology of nicotine and its therapeutic use in smoking cessation and neurodegenerative disorders.

D J Balfour1, K O Fagerström.   

Abstract

During the last decade, nicotine has been used increasingly as an aid to smoking cessation and has been found to be a safe and efficacious treatment for the symptoms of nicotine withdrawal. This period has also seen significant advances in our understanding of the mechanisms underlying the psychopharmacological responses to nicotine, including, particularly, those that have been implicated in nicotine addiction. This paper reviews this decade of progress in the specific context of the therapeutic application of nicotine to the treatment of smoking cessation. Other putative future applications, particularly in the treatment of neurodegenerative disorders, are also reviewed.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8981571     DOI: 10.1016/s0163-7258(96)00099-x

Source DB:  PubMed          Journal:  Pharmacol Ther        ISSN: 0163-7258            Impact factor:   12.310


  32 in total

1.  Positron emission tomography experience with 2-[¹⁸F]fluoro-3-(2(S)-azetidinylmethoxy)pyridine (2-[¹⁸F]FA) in the living human brain of smokers with paranoid schizophrenia.

Authors:  James Robert Brašić; Nicola Cascella; Anil Kumar; Yun Zhou; John Hilton; Vanessa Raymont; Andrew Crabb; Maria Rita Guevara; Andrew G Horti; Dean Foster Wong
Journal:  Synapse       Date:  2011-12-29       Impact factor: 2.562

2.  Nicotine psychopharmacology research: advancing science, public health, and global policy.

Authors:  Jack E Henningfield; Ian P Stolerman; Klaus A Miczek
Journal:  Psychopharmacology (Berl)       Date:  2006-03       Impact factor: 4.530

3.  The novel nicotinic receptor antagonist, N,N'-dodecane-1,12-diyl-bis-3-picolinium dibromide (bPiDDB), inhibits nicotine-evoked [(3)H]norepinephrine overflow from rat hippocampal slices.

Authors:  Andrew M Smith; Gurpreet K Dhawan; Zhenfa Zhang; Kiran B Siripurapu; Peter A Crooks; Linda P Dwoskin
Journal:  Biochem Pharmacol       Date:  2009-07-23       Impact factor: 5.858

Review 4.  Benefits and risks of pharmacological smoking cessation therapies in chronic obstructive pulmonary disease.

Authors:  Edwin J Wagena; Maurice P A Zeegers; Constant P van Schayck; Emiel F M Wouters
Journal:  Drug Saf       Date:  2003       Impact factor: 5.606

5.  The effect of nicotine in combination with various dopaminergic drugs on nigrostriatal dopamine in rats.

Authors:  Sanna Janhunen; Paula Mielikäinen; Päivi Paldánius; Raimo K Tuominen; Liisa Ahtee; Seppo Kaakkola
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2005-07-13       Impact factor: 3.000

Review 6.  Cholinergic System and Its Therapeutic Importance in Inflammation and Autoimmunity.

Authors:  Namrita Halder; Girdhari Lal
Journal:  Front Immunol       Date:  2021-04-15       Impact factor: 7.561

7.  Single photon emission computed tomography experience with (S)-5-[(123)I]iodo-3-(2-azetidinylmethoxy)pyridine in the living human brain of smokers and nonsmokers.

Authors:  James Robert Brasić; Yun Zhou; John L Musachio; John Hilton; Hong Fan; Andrew Crabb; Christopher J Endres; Melvin J Reinhardt; Ahmet S Dogan; Mohab Alexander; Olivier Rousset; Marika A Maris; Jeffrey Galecki; Ayon Nandi; Dean F Wong
Journal:  Synapse       Date:  2009-04       Impact factor: 2.562

8.  Carbon Nanotube Membranes for use in the Transdermal Treatment of Nicotine Addiction and Opioid Withdrawal Symptoms.

Authors:  Caroline L Strasinger; Nicole N Scheff; Ji Wu; Bruce J Hinds; Audra L Stinchcomb
Journal:  Subst Abuse       Date:  2009-03-18

Review 9.  Do smokers self-administer pure nicotine? A review of the evidence.

Authors:  Reuven Dar; Hanan Frenk
Journal:  Psychopharmacology (Berl)       Date:  2004-03-05       Impact factor: 4.530

10.  Nicotine induces sensitization of turning behavior in 6-hydroxydopamine lesioned rats.

Authors:  M L Gregório; E C Wietzikoski; M M Ferro; J L M Silveira; M A B F Vital; C Da Cunha
Journal:  Neurotox Res       Date:  2009-03-18       Impact factor: 3.911

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.